CClinicalTrials.gg
CompletedNCT05787522Updated Feb 12, 2026

Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk

An observational study in Lung Cancer, Breast Cancer and Esophageal Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate performance and clinical applicability of AI-assisted radiotherapy contouring software (iCurveE) for thoracic organs at risk. The main question it aims to answer is:

  • Does AI-assisted contouring (AI contouring with manual modification) offer greater accuracy and time efficiency compared to manual contouring? After screening, the qualified participants' thoracic CT images will be anonymized and segmented using three methods: manual, AI (AI-only), and AI-assisted contouring. The researchers will compare the results generated by the three different contouring methods with the ground truth established by expert consensus, in order to evaluate both accuracy and time-related parameters
02

Conditions studied

  • Lung Cancer
  • Breast Cancer
  • Esophageal Cancer

Keywords

  • Artificial Intelligence
  • Radiotherapy
  • contouring
  • thoracic organs at risk
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 500 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 484 studies on the registry; 286 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This trial will enroll 500 patients with lung, esophageal, or breast cancer, who are scheduled to receive thoracic radiotherapy across five clinical cancer institutes.

Inclusion criteria

  1. ≥18 years old, no gender limit.
  2. Patients diagnosed with breast cancer, lung cancer, or esophageal cancer, who are scheduled for chest CT scanning followed by thoracic radiotherapy.
  3. CT slice thickness ≤5mm.
  4. Patients understand the goal of the trial, are willing to attend the trial and sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Congenital malformations or abnormal anatomical structures resulting from non-tumor factors in the scan area.
  2. Artifact, prosthesis or implantation causing images undistinguishable.
  3. CT images not conforming to DICOM standards.
  4. Investigators consider not suitable.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (actual)
Patient registry
No

Groups and cohorts

  • Independent manual contouring

    Manual contouring refers to physicians using the brush tool on the contouring platform to segment thoracic organs at risk manually, without the use of auto-segmentation tools.

  • AI contouring

    AI contouring refers to the auto-segmentation results generated by the Res-SE Net model, with the model integrated into the auto-segmentation software (iCurveE).

  • AI-assisted contouring

    After generating the AI contouring results, investigators will import them into the contouring platform and perform manual modifications, producing the AI-assisted contouring.

06

What researchers measure

Primary outcomes

  1. volumetric DICE similarity coefficient, vDSC

    vDSC= 2×(A∩B)/(A+B), where A refers to the volume of the ground truth, and B refers to the volume of the manual, AI, or AI-assisted contour.

    Time frame: Within 6 months after enrollment

  2. Contouring time (min)

    Manual contouring time is recorded from the time the CT is loaded on the contouring platform to the completion of contouring. AI-assisted contouring time is defined as the sum of the auto-segmentation model runtime, the transfer to the contouring platform, and the subsequent manual modification.

    Time frame: Within 6 months after enrollment

Secondary outcomes

  1. 95th percentile Hausdorff Distance, HD95

    HD95(A, B) = max (h95(A, B), h95(B, A)), where h95(A, B) is the 95th percentile of the shortest distances from all points on surface A to surface B, and vice-versa for h95(B, A). A represents the ground truth and B represents the manual, AI or AI-assisted delineation

    Time frame: Within 6 months after enrollment

  2. Surface DICE similarity coefficient, sDSC

    sDSC = (\|S(A) ∩ S(B)τ\| + \|S(B) ∩ S(A)τ\|) / (\|S(A)\| + \|S(B)\|), where S(A) and S(B) are the sets of points on the surfaces of A and B, S(B)τ represents the points on surface B that are within the tolerance τ of surface A, and S(A)τ represents the points on surface A that are within the tolerance τ of surface B. A represents the ground truth and B represents the manual, AI or AI-assisted delineation

    Time frame: Within 6 months after enrollment

  3. Rate of time efficiency improvement

    Rate of efficiency time improvement= (manual contouring duration - AI-assisted contouring duration)/ manual contouring duration\*100%

    Time frame: Within 6 months after enrollment

  4. Volumetric revision index, VRI

    VRI = \[(A- A∩B) + (B- A∩B)\] /A, where A refers to the volume of the ground truth, and B refers to the volume of the manual, AI, or AI-assisted contour.

    Time frame: Within 6 months after enrollment

  5. Recall, Rec

    Rec = \| A∩B\| / A, where A refers to the volume of the ground truth, and B refers to the volume of the manual, AI, or AI-assisted contour.

    Time frame: Within 6 months after enrollment

  6. Precision, Pre

    Pre= \|A∩B\| / B, where A refers to the volume of the ground truth, and B refers to the volume of manual, AI, or AI-assisted contour.

    Time frame: Within 6 months after enrollment

  7. Relative volume difference, RVD

    RVD = \|A-B\| /A, where A refers to the volume of the ground truth, and B refers to the volume of the manual, AI, or AI-assisted contour.

    Time frame: Within 6 months after enrollment

  8. Investigators satisfaction score for AI contouring

    Evaluated on a 1-5 Likert scale: 1 - strongly dissatisfied, 2 - dissatisfied, 3 - neutral, 4 - satisfied, 5 - strongly satisfied.

    Time frame: Within 6 months after enrollment

Other outcomes

  1. Number of adverse events, AEs

    Participant Adverse events during CT scanning

    Time frame: Within 1 day after CT scanning

  2. Number of device defects during AI-assisted contouring

    Number of failures in generating, transferring, or saving auto-segmentation results

    Time frame: Within 6 months after enrollment

07

Study locations

1 site
  • Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy
    Tianjin, Tianjin Municipality 300060, China
08

References and documents

Publications

  • Niu G, Guan Y, Zhang Y, Song Y, Yan M, Li S, Liu T, Huang S, Chen J, Wang X, Zhang W, Meng M, Liu Y, Chen J, Fu Y, Zhao D, Huang J, Yang K, Cao J, Yuan H, Guo S, Pei X, Wu D, Nan Y, Yan Z, Lu Y, Zhao L, Yuan Z. A prospective multicenter trial of deep learning auto-segmentation for organs at risk in thoracic radiotherapy. Nat Commun. 2026 Mar 31;17(1):4633. doi: 10.1038/s41467-026-70863-9. PubMed 41917034 ↗

Individual participant data

Plan to share: Yes — The protocol of this study are available from the corresponding author upon reasonable request after the manuscript publication.

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05787522
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
Guangzhou Perception Vision Medical Technology Co. Ltd, People's Hospital of Guangxi Zhuang Autonomous Region, Shanxi Province Cancer Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Responsible party
Sponsor
First posted
Mar 28, 2023
Start date
Sep 30, 2022
Primary completion
Jul 27, 2023
Completion
Mar 6, 2024
Last update
Feb 12, 2026

Study contacts

Zhiyong Yuan, Ph.D.
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion